Anti-MMP2 [CA-4001 / CA719E3C] antibody

Overview

NO ED

• Product nameAnti-MMP2 [CA-4001 / CA719E3C] antibodySee all MMP2 primary antibodies ...
• Description

  Mouse monoclonal [CA-4001 / CA719E3C] to MMP2

• Specificityab3158 reacts with only the proform of MMP-2 and shows no cross-reaction with pro and active forms of MMP-9.1
• Tested applicationsFlow Cyt, IHC-P, IP, WB
• Species reactivity

  Reacts with: Human
  Predicted to work with: Mouse, Rat

• Immunogen

  Synthetic peptide:

  APSPIIKFPGD-VAPKTDK

  , corresponding to amino acids 30-47 of MMP2.

   

  Run BLAST with Run BLAST with 

• EpitopeN-terminal (APSPIIKFPGD-VAPKTDK).
• Positive control
  • Conditioned, serum-free medium from (TPA-treated) HFL-1 cells. Placenta.

Properties

• FormLiquid
• Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
• Storage buffer10mM PBS, pH7.4, 0.2%BSA, 0.09% sodium azide

• Concentration500 µl at 0.2 mg/ml 

• PurityProtein G purified
• ClonalityMonoclonal
• Clone numberCA-4001 / CA719E3C
• IsotypeIgG1
• Research Areas
  • Cardiovascular
  •  
  • Angiogenesis
  •  
  • Adhesion / ECM
  •  
  • Matrix Metalloproteinases
  • MMP
  • Cancer
  •  
  • Invasion/microenvironment
  •  
  • ECM
  •  
  • Extracellular matrix
  •  
  • MMPs
  • Cell Biology
  •  
  • Proteolysis / Ubiquitin
  •  
  • Proteolytic enzymes
  •  
  • Metalloprotease
  • MMPs
  • Cancer
  •  
  • Tumor biomarkers
  •  
  • Enzymes
  •  
  • MMPs
  • Cancer
  •  
  • Cancer Metabolism
  •  
  • Response to hypoxia
  • Metabolism
  •  
  • Pathways and Processes
  •  
  • Metabolism processes
  •  
  • Hypoxia
  • Metabolism
  •  
  • Types of disease
  •  
  • Cancer

Applications

Our Abpromise guarantee covers the use of ab3158 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application	Abreviews	Notes
Flow Cyt		Use 1-2µg for 106 cells.
IHC-P		Use a concentration of 10 µg/ml. 1:20 dilution
IP		Use at an assay dependent dilution.
WB		Use at an assay dependent dilution. Detects a band of approximately 72 kDa (predicted molecular weight: 74 kDa). 1:200-1:400 for 2hrs at RT.

Target

• FunctionUbiquitinous metalloproteinase that is involved in diverse functions such as remodeling of the vasculature, angiogenesis, tissue repair, tumor invasion, inflammation, and atherosclerotic plaque rupture. As well as degrading extracellular matrix proteins, can also act on several nonmatrix proteins such as big endothelial 1 and beta-type CGRP promoting vasoconstriction. Also cleaves KISS at a Gly-
  -Leu bond. Appears to have a role in myocardial cell death pathways. Contributes to myocardial oxidative stress by regulating the activity of GSK3beta. Cleaves GSK3beta in vitro.
  PEX, the C-terminal non-catalytic fragment of MMP2, posseses anti-angiogenic and anti-tumor properties and inhibits cell migration and cell adhesion to FGF2 and vitronectin. Ligand for integrinv/beta3 on the surface of blood vessels.
• Tissue specificityProduced by normal skin fibroblasts. PEX is expressed in a number of tumors including gliomas, breast and prostate.
• Involvement in diseaseDefects in MMP2 are the cause of Torg-Winchester syndrome (TWS) [MIM:259600]; also known as multicentric osteolysis nodulosis and arthropathy (MONA). TWS is an autosomal recessive osteolysis syndrome. It is severe with generalized osteolysis and osteopenia. Subcutaneous nodules are usually absent. Torg-Winchester syndrome has been associated with a number of additional features including coarse face, corneal opacities, patches of thickened, hyperpigmented skin, hypertrichosis and gum hypertrophy. However, these features are not always present and have occasionally been observed in other osteolysis syndromes.
• Sequence similaritiesBelongs to the peptidase M10A family.
  Contains 3 fibronectin type-II domains.
  Contains 4 hemopexin-like domains.
• DomainThe conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
• Post-translational
  modificationsPhosphorylation on multiple sites modulates enzymatic activity. Phosphorylated by PKC in vitro.
  The propeptide is processed by MMP14 (MT-MMP1) and MMP16 (MT-MMP3). Autocatalytic cleavage in the C-terminal produces the anti-angiogenic peptide, PEX. This processing appears to be facilitated by binding integrinv/beta3.
• Cellular localizationSecreted > extracellular space > extracellular matrix. Membrane. Nucleus. Colocalizes with integrin alphaV/beta3 at the membrane surface in angiogenic blood vessels and melanomas. Found in mitochondria, along microfibrils, and in nuclei of cardiomyocytes.
• Information by UniProt

• Database links

  • Entrez Gene: 4313 Human
  • Entrez Gene: 17390 Mouse
  • Entrez Gene: 81686 Rat
  • Omim: 120360 Human
  • SwissProt: P08253 Human
  • SwissProt: P33434 Mouse
  • SwissProt: P33436 Rat
  • Unigene: 513617 Human